Medtronic and Biotronik both took steps forward this week with their pacemaker hardware designed to target newly emerging ...

Medtronic (NYSE: MDT) announced today that it received FDA approval for an expanded indication for its OmniaSecure defibrillation lead.

A 173-patient randomized trial in HFrEF (LVEF ≤35%) with LBBB (QRS ≥130 ms) showed CSP was inferior to BiVP for a hierarchical 12‑month composite endpoint. Worse outcomes with CSP were reflected by an ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) approval for an expanded indication for the OmniaSecure™ defibrillation lead. Now ...

The findings suggest that use of the pacing technique during CRT should be reserved for expert operators, at least for now.

Two multicenter trials drew different conclusions about the value of conduction system relative to biventricular pacing for ...

OmniaSecure is now the first defibrillation lead approved for placement in the left bundle branch.

SAN FRANCISCO, CA—Attendees of Heart Rhythm 2022 heard results from numerous studies investigating the impact of conduction-system pacing, which includes both His-bundle and left bundle branch (LBB) ...

Please provide your email address to receive an email when new articles are posted on . Left bundle branch pacing was achieved for the first time via leadless pacemaker. Implantation failure rate was ...

The European Society of Cardiology (ESC) has released a groundbreaking consensus statement on conduction system pacing (CSP), marking a significant milestone in the evolution of pacing therapy. The ...

NEW ORLEANS -- Among patients with heart failure, conduction system pacing-guided cardiac resynchronization therapy was associated with improvements in left ventricular ejection fraction (LVEF) ...